Genomic prostate score and treatment selection in favourable intermediate‐risk prostate cancer

Documenti analoghi

• PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer
  di: Nicole Handa, et al.
  Pubblicazione: (2025)
• First validation of the Prostatype® P‐score in an Asian cohort: Improving risk stratification for prostate cancer
  di: See‐Tong Pang, et al.
  Pubblicazione: (2025)
• Oncological outcomes post focal low‐dose‐rate brachytherapy in low‐intermediate risk prostate cancer
  di: Mohammadmehdi Adhami, et al.
  Pubblicazione: (2026)
• Variation in harms and benefits of prostate‐specific antigen screening for prostate cancer by socio‐clinical risk factors: A rapid review
  di: Abel Tesfai, et al.
  Pubblicazione: (2024)
• Comparing outcomes of Aquablation versus holmium laser enucleation of prostate in the treatment of benign prostatic hyperplasia: A network meta‐analysis
  di: Ansh Bhatia, et al.
  Pubblicazione: (2024)